Cost-effectiveness comparison of generic drugs of Futibatinib

Futibatinib (Futibatinib) is a new generation of irreversible FGFR inhibitor, mainly used for patients with intrahepatic cholangiocarcinoma (CCA) with positive FGFR2 gene fusion or rearrangement. Since these patients have usually received systemic treatment and have relatively limited treatment options, forbatinib has attracted great attention after being approved overseas. However, the high price of original drugs puts many patients under great financial pressure during long-term medication. Therefore, the cost-effectiveness of generic drugs has become a common concern of patients and their families.

Judging from the current market situation, the original drug forbatinib has been launched in some countries and regions, but the overall price is still at a high level among targeted drugs. In contrast, the emergence of the Lao version of forbatinib generics provides patients with a more accessible choice. The common specifications of this generic drug are 4 mg × 35 tablets, and the price is about 2,500 yuan. Compared with the original version, the cost is significantly lower, and it is more suitable for patients who require long-term or continuous treatment.

In terms of the drugs themselves, overseas public information shows that the legally marketed generic drugs are consistent with the original drugs in terms of active ingredients, dosage design and targets, and they all exert inhibitory effects on theFGFR2 signaling pathway. Judging from patient feedback, as long as the source is regular and the production process meets quality standards, the application experience of generic drugs in actual treatment is not fundamentally different from that of original drugs. This is also the core of its cost-effective advantage.

It should be noted that when choosing generic drugs, patients should pay more attention to the reliability of the purchasing channel rather than simply pursuing low prices. It is recommended to obtain product information through formal cross-border drug channels or professional medical service platforms, and fully communicate with the attending doctor before use to ensure the consistency of dose connection, treatment course management and overall treatment plan.

Reference materials:https://www.lytgobi.com/